111 related articles for article (PubMed ID: 16033808)
1. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study.
Park YJ; Chang LC; Liang JF; Moon C; Chung CP; Yang VC
FASEB J; 2005 Sep; 19(11):1555-7. PubMed ID: 16033808
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study.
Park YJ; Liang JF; Ko KS; Kim SW; Yang VC
J Gene Med; 2003 Aug; 5(8):700-11. PubMed ID: 12898639
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide.
He H; Ye J; Liu E; Liang Q; Liu Q; Yang VC
J Control Release; 2014 Nov; 193():63-73. PubMed ID: 24943246
[TBL] [Abstract][Full Text] [Related]
4. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
[TBL] [Abstract][Full Text] [Related]
5. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
6. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.
Chang LC; Lee HF; Yang Z; Yang VC
AAPS PharmSci; 2001; 3(3):E17. PubMed ID: 11741268
[TBL] [Abstract][Full Text] [Related]
9. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.
Shin MC; Zhang J; David AE; Trommer WE; Kwon YM; Min KA; Kim JH; Yang VC
J Control Release; 2013 Nov; 172(1):169-178. PubMed ID: 23973813
[TBL] [Abstract][Full Text] [Related]
10. Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.
Shin MC; Zhao J; Zhang J; Huang Y; He H; Wang M; Min KA; Yang VC
J Biomed Mater Res A; 2015 Jan; 103(1):409-419. PubMed ID: 24733757
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine.
Byun Y; Chang LC; Lee LM; Han IS; Singh VK; Yang VC
ASAIO J; 2000; 46(4):435-9. PubMed ID: 10926141
[TBL] [Abstract][Full Text] [Related]
12. Protamine as an efficient membrane-translocating peptide.
Reynolds F; Weissleder R; Josephson L
Bioconjug Chem; 2005; 16(5):1240-5. PubMed ID: 16173804
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight protamine: a potential nontoxic heparin antagonist.
Byun Y; Singh VK; Yang VC
Thromb Res; 1999 Apr; 94(1):53-61. PubMed ID: 10213181
[TBL] [Abstract][Full Text] [Related]
14. Truncations of gelonin lead to a reduction in its cytotoxicity.
Li Z; Qu Y; Li H; Yuan J
Toxicology; 2007 Mar; 231(2-3):129-36. PubMed ID: 17222956
[TBL] [Abstract][Full Text] [Related]
15. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
16. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Kim D; Jeon C; Kim JH; Kim MS; Yoon CH; Choi IS; Kim SH; Bae YS
Exp Cell Res; 2006 May; 312(8):1277-88. PubMed ID: 16466653
[TBL] [Abstract][Full Text] [Related]
18. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.
Meriläinen O; Hakkarainen T; Wahlfors T; Pellinen R; Wahlfors J
Int J Oncol; 2005 Jul; 27(1):203-8. PubMed ID: 15942661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
